Established commercial functions for a novel skin-based test for Alzheimer's Disease, including marketing, market access, and sales. Developed revenue cycle model incorporating pre-test insurance verification, sample biopsy kit fulfillment process, and billing. Hired, developed, and managed two sales personnel to achieve 100% lab capacity, with >90% of samples reimbursed at full Medicare rates.

Initiated marketing role in liver diagnostic startup and then moved to Market Access to focus on reimbursement and market development initiatives.

Reporting to the franchise Vice President, responsible for contributing to and coordinating Commercial insights into cross-functional Brand Plans at the Global and Country levels.
 Provided market insights supporting product development and commercialization for the HCV market.
 Led and supported the implementation of key initiatives with the US Field Organization and Marketing teams.
 Liaison between Marketing, Global Clinical Development, HEOR, and US Medical Affairs.
 Led the development and execution of global complementary diagnostic strategies and partnerships to improve patient identification, activation, and treatment for HCV with Viekira® regimens.
 Led the commercialization of the launch of Moderiba® (ribavirin) to facilitate early market access ex-US.
 In conjunction with Area leadership and internal stakeholders, led a team to develop and implement country-level forecasts and resource plans, launch tools, competitive assessments, onboarding and in-field team training

Senior Marketing Director – Multiple Sclerosis, Cambridge, MA (2007-2009)
 Coordinated development of the Global commercial platform for alemtuzumab in MS with Bayer-Schering. With the restructured relationship in mid-2009, became responsible for marketing planning.
 Developed and executed the Global prelaunch marketing platform, coordinated the US pricing strategy, and executed congress, KOL, advisory, and brand development plans in coordination with key stakeholders. Additionally, provided commercial input into REMS, publications, and investigator management.
 Managed one Associate Product Manager to implement the market research plan and product forecasting.

Senior Director – Global Marketing, Cambridge, MA (2004–2007)
Responsible for the development and implementation of commercialization plans for late-stage products
 Reporting to the Business Unit President, led the commercialization activities for tolevamer, a novel toxin binder to treat C. difficile-associated disease.
o

Marketing Director – Hepatitis, Nutley, NJ (2003-2004)
Reporting to the Vice President, led a team comprised of a Brand Director, a Product Director, and six Product Managers in the development and execution of key initiatives and tactics. To achieve market dominance, implemented initiatives designed to optimize positioning, improve patient outcomes, and expand the treater pool.

 Led the January 2003 launch of PEGASYS® (peginterferon alfa 2a) in combination with COPEGUS® (ribavirin, USP), achieving a new prescription market share of 60% by March 2004. Combined net sales in 2003 exceeded $500 million (33% above goal), two years ahead of the strategic plan targets.
 Provided strategic direction for label expansion, including HIV/HCV co-infection, normal ALT, and HBV.
 Developed the strategic platform to drive market expansion, including innovative patient management programs, outreach pilots, and educational programs.

Brand Director, Nutley, NJ (2000-2002)
Reporting to the Vice Pr

Product Manager, Vaccine Division, West Point, PA (1997-1999)
As sole Product Manager for the US market, responsible for strategic plans, tactical implementation, financial and production forecasting, clinical development programs, and support for customer marketing initiatives for the VAQTA® vaccine (hepatitis A, inactivated).
 Implemented a switch strategy for key segments, resulting in 1997 sales performance of 40% above Plan. In 1998, further enhancements led to sales exceeding the plan by 35%.
Manager, Business Development, US Human Health, West Point, PA (1995-1997)
Supported therapeutic area product teams formulating strategies and negotiating contracts with partner organizations.
Professional Representative, US Human Health, Bronx & Westchester County, NY (1993-1995)
 1995 Recipient of the Vice President’s Club Award for sales performance and leadership.
Manager, MIR Pricing, Economic Affairs, Whitehouse Station, NJ (1991-1993)
Pricing Analyst Merck Intercontinental Region